Study protocol of a multicenter, randomized, non-inferiority, open-label study investigating the efficacy of a fixed-dose combination regimen of dapagliflozin/metformin versus co-administered dual therapy based on glycemic control, satisfaction and adherence in patients with newly diagnosed type 2 diabetes mellitus
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: The combination of dapagliflozin and metformin is commonly used as an initial therapy for patients with type 2 diabetes mellitus (T2DM) with high glycated hemoglobin (HbA1c) levels. Although bioequivalence has been established for the fixed-dose combination (FDC) of dapagliflozin/metformin extended-release (XR) compared to the co-administration of dapagliflozin and metformin XR, it remains uncertain whether the efficacy of dapagliflozin/metformin FDC is comparable to that of co-administration. Additionally, it is still unclear whether fixed-dose combinations offer advantages in terms of patient adherence and satisfaction. This study aims to compare the dapagliflozin/metformin XR FDC with co-administration of dapagliflozin and metformin XR for efficacy in terms of glycemic control, patient satisfaction, quality of life and adherence in Chinese patients with newly diagnosed T2DM. Methods and analysis: This multicenter, randomized, non-inferiority, open-label clinical trial enrolled 632 patients with T2DM (HbA1c 7.5-10%) in 35 research centers in China. After enrollment, the patients will be randomly assigned to receive either FDC treatment (10 mg dapagliflozin and 1000 mg metformin XR) or co-administered 10 mg dapagliflozin and 1000 mg metformin XR tablets for 24 weeks. The primary endpoint was the change in HbA1c level from baseline after 24 weeks of treatment. Secondary endpoints included the proportion of patients achieving HbA1c below 7.0%, absolute changes in fasting plasma glucose and postprandial glucose from baseline to week 24, the difference in patient satisfaction measured with the diabetes treatment satisfaction questionnaire, medication usage measured with adherence to refills and medications scale for diabetes between the two groups at week 24, change from baseline in diabetes quality of life questionnaire score at week 12 and week 24, and safety. Continuous glucose monitoring will also be used to evaluate the benefits of FDC compared with co-administration on glycemic variability. Discussion: This study, as the first of its kind, will provide comparative data on the efficacy of the dapagliflozin/metformin XR FDC and co-administration of dapagliflozin and metformin XR in terms of glycemic control, patient satisfaction, quality of life and adherence. These data will help clinicians make more informed decisions for patients with type 2 diabetes and may improve medication burden, treatment adherence, and satisfaction.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Study protocol of a multicenter, randomized, non-inferiority, open-label study investigating the efficacy of a fixed-dose combination regimen of dapagliflozin/metformin versus co-administered dual therapy based on glycemic control, satisfaction and adherence in patients with newly diagnosed type 2 diabetes mellitus
- Date Crossref
- 04/11/2025
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Capital Medical University Beijing Chao-Yang Hospital pays non établi dans la noticeÉtablissement de santé
-
Beijing Chaoyang Emergency Medical Center pays non établi dans la noticeÉtablissement de santé
-
Dingxi City People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Zhuhai People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Southern Medical University Shenzhen Hospital Department of Endocrinology pays non établi dans la noticeÉtablissement de santé
-
Changshu No.1 People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Third People's Hospital of Hefei pays non établi dans la noticeÉtablissement de santé
-
Nantong University pays non établi dans la noticeUniversité ou école supérieure
-
Second People's Hospital of NanTong pays non établi dans la noticeÉtablissement de santé
-
Jiangyin People's Hospital pays non établi dans la noticeÉtablissement de santé
-
The People's Hospital of Dingzhou Department of Endocrinology pays non établi dans la noticeÉtablissement de santé
-
The People's Hospital of Zhuji Department of Endocrinology pays non établi dans la noticeÉtablissement de santé
Beijing Chao-Yang Hospital — Capital Medical University, Beijing Chaoyang Emergency Medical Center et Dingxi City People's Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.